LY-2928057
- Generic Name
- LY-2928057
A Study of LY2928057 in Hemodialysis Participants
Phase 1
Completed
- Conditions
- Kidney Disease, ChronicRenal Insufficiency, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01991483
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Davita Clinical Research, DN, Lakewood, Colorado, United States
A First Human Study of a Ferroportin Antibody
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT01330953
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath